comprehensive -WSS

comprehensive

author：fashion 2025-09-27 10:03:45 - browse：661

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Lack of health data on LGBTQ+ people has serious consequences

WSS

A new approach to psychiatric drug development

Florida health officials providing scant details on measles cases

Streamlined flu vaccines recommended by FDA advisory panel

Immune cells and nerve overgrowth may explain recurring UTI pain

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Using force crossed my mind when examining a defiant young patient

knowledge

comprehensive

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

Longer MASH drug regimen improved liver, Akero study finds

Tori Bowie and the unacceptable rates of Black maternal death

Laying a path for careers in science

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why Talkspace is targeting Medicare, a tricky market

In Memoriam: Notable people who died in 2023

Elisabeth Bik tackles the widespread issue of research misconduct

Medicare proposal to cover medical devices draws a mixed reaction

Harvard's David Sinclair gets blowback over aging

hotspot

Color Health wants to make cancer screenings convenient

CDC advisory group OKs chikungunya vaccine

Stem cell biologist probes earliest stages of human development

Medicare Advantage isn’t working — for anyone

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Redefining sustainability for the pharmaceutical industry

knowledge

leisure time

hotspot

knowledge